Journal
CURRENT OPINION IN BIOTECHNOLOGY
Volume 21, Issue 6, Pages 780-786Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2010.09.013
Keywords
-
Funding
- Fogarty International Center
- National Cancer Institute, National Institute of Allergy and Infectious Diseases
- National Institute of Mental Health
- National Institute on Drug Abuse
- National Heart Lung and Blood Institute
- National Center for Complementary and Alternative Medicine
- Office of Dietary Supplements
- National Institute of General Medical Sciences
- Biological Sciences Directorate of the National Science Foundation
- Office of Biological and Environmental Research of the U.S. Department of Energy [U01 TW00313]
- International Cooperative Biodiversity Groups
- National Research Initiative of the Cooperative State Research, Education and Extension Service, USDA [2008-35621-04732]
- Kraft Foods
- NOAA
Ask authors/readers for more resources
Marine microbes have received growing attention as sources of bioactive metabolites and offer a unique opportunity to both increase the number of marine natural products in clinical trials as well as expedite their development. This review focuses specifically on those molecules currently in the clinical pipeline that are established or highly likely to be produced by bacteria based on expanding circumstantial evidence. We also include an example of how compounds from harmful algal blooms may yield both tools for measuring environmental change as well as leads for pharmaceutical development. An example of the karlotoxin class of compounds isolated from the dinoflagellate Karlodinium veneficum reveals a significant environmental impact in the form of massive fish kills, but also provides opportunities to construct new molecules for the control of cancer and serum cholesterol assisted by tools associated with rational drug design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available